Japan's PeptiDream to work with Merck in developing COVID-19 therapies

PeptiDream

12/06/2020 04:34

TOKYO, June 12 (Reuters) - Japanese drug-discovery company
PeptiDream Inc  4587.T  said on Friday it would collaborate with
Merck & Co  MRK.N  in developing COVID-19 therapies.
    The companies will work to develop peptide therapeutics that
may be effective against multiple coronavirus strains, they said
in a release. The agreement builds on a research and licensing
partnership announced in 2015.
    PeptiDream specialises in constrained peptides, types of
amino acids that can carry various cargoes to specific types of
cells.


 (Reporting by Rocky Swift; Editing by Christian Schmollinger)
 ((rocky.swift@tr.com))